Table 1 Patient characteristics
All (n = 61) | Valacyclovir (n = 15) | Valganciclovir (n = 16) | Foscarnet (n = 30) | P a | ||
|---|---|---|---|---|---|---|
Median age, years (range) | 41 (16–66) | 47 (18–61) | 50 (30–57) | 37 (16–66) | 0.017 | |
Male, N (%) | 31 (50.8) | 9 (60.0) | 5 (31.3) | 27 (56.7) | 0.186 | |
Diagnosis, N (%) | 0.509 | |||||
Acute myeloid leukemia | 30 (49.2) | 7 (46.7) | 9 (56.3) | 14 (46.7) | ||
Acute lymphoid leukemia | 13 (21.3) | 3 (20.0) | 1 (6.3) | 9 (30.0) | ||
Non-Hodgkin’s lymphoma | 2 (3.3) | 1 (6.7) | 1 (6.3) | 0 (0.0) | ||
Myelodysplastic syndrome | 6 (9.8) | 1 (6.7) | 1 (6.3) | 4 (13.3) | ||
Others | 10 (16.4) | 3 (20.0) | 4 (25.0) | 3 (10.0) | ||
Conditioning regimen, N (%) | 0.374 | |||||
Myeloabalative | 32 (53.3) | 9 (60.0) | 11 (68.8) | 12 (41.4) | ||
Non-Myeloabalative | 14 (23.3) | 2 (13.3) | 3 (18.8) | 9 (31.0) | ||
Reduced Intensity | 14 (23.3) | 4 (26.7) | 2 (12.5) | 8 (27.6) | ||
Donor type, N (%) | 0.078 | |||||
Related | 31 (50.8) | 11 (73.3) | 10 (62.5) | 10 (33.3) | ||
Unrelated | 21 (34.4) | 2 (13.3) | 5 (31.3) | 14 (46.7) | ||
Cord Blood | 9 (14.8) | 2 (13.3) | 1 (6.25) | 6 (20.0) | ||
CMV serologic status, N (%) | 0.586 | |||||
Donor-/recipient+ | 9 (14.8) | 1 (6.7) | 3 (18.8) | 5 (16.7) | ||
Donor+/recipient+ | 52 (85.3) | 14 (93.3) | 13 (81.3) | 25 (83.3) | ||
GVHD (during study) | 0.155 | |||||
None | 27 (44.3) | 5 (33.3) | 4 (25.0) | 18 (60.0) | ||
Grade I-II | 30 (49.2) | 9 (60.0) | 10 (62.5) | 11 (36.7) | ||
Grade II-IV | 4 (6.6) | 1 (6.7) | 2 (12.5) | 1 (33.3) | ||
GVHD treatment | 0.119 | |||||
None | 25 (41.0) | 5 (33.3) | 3 (18.8) | 17 (56.7) | ||
Steroids | 30 (49.1) | 9 (60.0) | 11 (68.9) | 10 (33.3) | ||
Others | 6 (9.8) | 1 (6.7) | 2 (12.5) | 3 (10.0) | ||
Pre-treatment laboratory results, median (range) | ||||||
Creatinine (μM) | 78 (40–240) | 86 (46–182) | 72 (44–240) | 78 (40–205) | 0.601 | |
ANC (x103/mm3) | 2.6 (0.2-22.8) | 2.4 (0.2-6.6) | 3.6 (1.1-15.6) | 1.7 (0.8-22.8) | 0.093 | |
Platelet (x103/mm3) | 64 (7–260) | 98 (15–197) | 68 (7–244) | 32.5 (8–260) | 0.053 | |